The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.

Anti-Filgrastim ADA Quantitative ELISA Kit

(No reviews yet) Write a Review
SKU:
HUMB00038
$1,136

Description

ELISA Kit Technical Manual

Anti-Filgrastim ADA Quantitative ELISA Kit

Enzyme immunoassay for the quantitative determination of specific antibodies to Filgrastim in human serum and plasma with confirmation reagent (for 20 samples)The ELISA Genie Antibody to filgrastim Enzyme-Linked-ImmunoSorbent Assay (ELISA) Kit is intended for the quantitative determination of antibodies to filgrastim in serum and plasma. It is for professional use only.

Product Information

ApplicationFree drug
Required Volume (μl)10
Total Time (min)200
Sample TypeSerum, Plasma
Number of Assays96
Detection Limit (ng/mL)3 (ng/mL)
Spike Recovery (%)85-115%
Shelf Life (year)6 Months

About Anti-Filgrastim ADA Quantitative

Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a GCSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase. Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Filgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. When tbo-filgrastim is administered to cancer patients, it took 3-5 days to reach maximum absolute neutrophil count (ANC). Levels of neutrophils returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16-19% increase in the ANCmax and a 33-36% increase in the area under the effect curve for ANC.

Anti-Filgrastim ADA Quantitative ELISA Kit test principle

The Elisa Genie Antibody to Filgrastim ELISA is a sandwich assay for the determination of antibodies against filgrastim in serum and plasma samples. During the first incubation period, the drug filgrastim coated on the wall of the microtiter wells captures the antibodies to filgrastim in patient serum and plasma samples. After washing away the unbound components from samples, a Peroxidase-labelled conjugate (which detects IgG, IgM, IgA and IgE antibodies) is added to each well and then incubated. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of antibodies to filgrastim in sample.

Trademarks

NEUPOGEN® is the Amgen Inc. trademark for filgrastim

View AllClose